

Cellzome – a world leader in chemo-proteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates

Cellzome is a world leader in **chemoproteomics, transforming the sciences of epigenetics and signal transduction** into novel drug candidates in inflammatory diseases and oncology. The Company maintains the highest levels of scientific expertise and has active collaborations with the foremost academic laboratories around the world.

Cellzome's technologies work with native proteins in a physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases.

Cellzome is a privately-held, international, company located in Heidelberg, Germany and Cambridge, UK employing about 100 people.

Management team

has strong scientific and commercial credentials. The Company is also backed by some of the biotech industry's most experienced investors.

Strategy

The Company aims to commercialize its technology and assets by building a small molecule drug candidate pipeline in inflammation and oncology and by collaborating with pharmaceutical partners.

Technology

Episphere™ is being used to identify novel drug candidates for epigenetic targets in their protein complexes.

Kinobeads™ can define the target profile of kinase inhibitor drugs and is used as a versatile assay in screening and lead optimization using native kinases directly from cells and tissues.

Collaborations

- **Episphere™ collaboration** in inflammatory diseases with GSK. A worldwide strategic drug discovery alliance in the field of epigenetics.
- **Kinobeads™ collaboration** in inflammatory diseases with GSK. A worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.
- **Collaborations** with both Johnson & Johnson and Novartis were successfully completed.

Cellzome has a track record of successful partnership with the pharmaceutical industry. Partnering with some of the leading pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis, our feedback has always been extremely positive. Specifically, our partners see us as creative, transparent, timely, professional and with the highest standards of integrity producing science of the highest quality.

Cellzome Inc.

Founded: May 2000

Number of Employees: about 100

Board of Directors

Charles Cohen, PhD

Chairman,
Advent International

Timothy P. W. Edwards

Chief Executive Officer

Johnston L. Evans

Invesco Private Capital

Jason S. Fisherman, MD

Advent International

Jean-François Formela, MD, MBA

Atlas Venture

Stelios Papadopoulos, PhD

Francesco De Rubertis, PhD

Index Ventures

Senior Management Team

Timothy P. W. Edwards

Chief Executive Officer

David Simmons, PhD, MBA

Chief Scientific Officer

Jane Dancer, PhD, MBA

Vice President Business
Development

Gerard Drewes, PhD

Vice President Discovery Research

Richard Hale, PhD

Vice President Development
Projects & UK Site Head

Gitte Neubauer, PhD

Vice President Research
Operations

Nigel Ramsden, PhD

Vice President Drug Discovery

Oliver Rausch, PhD

Vice President Biology

Markus Reinhard

Vice President Finance &
Administration

Alan Watt, PhD, MBA

Vice President Therapeutics

Locations

Cellzome AG

Meyerhofstrasse 1
69117 Heidelberg
Germany

Tel: +49 (0) 6221 137 57 0

Fax: +49 (0) 6221 137 57 201

Cellzome Limited

Chesterford Research Park
Little Chesterford
Cambridge, CB10 1XL
United Kingdom

Tel: +44 (0) 1799 532 800

Fax: +44 (0) 1799 532 801

Investors

Advent International

Atlas Venture

Astellas Venture Capital

Biofrontier Partners

Heidelberg Innovation

Index Ventures

Invesco Private Capital

SV Life Sciences

SG Asset Management

Sofinnova Partners

Recent News

December 2011: Cellzome awarded UK's Technology Strategy Board grant as part of the Regenerative Medicine Programme

December 2011: Cellzome Founder wins EU Women Innovators Award. Dr. Gitte Neubauer awarded first prize for the foundation of Cellzome

October 2011: Proteomic Study Published in the Journal Nature Paves the Way for New Treatment for Incurable Leukaemia Using an Epigenetic Inhibitor